I was reading my emails this morning and came across one from the Foundation for Women’s Cancers, announcing September as Gynecologic Cancer Awareness Month. Their social media campaign centered on the hashtag above, with a focus on clinical trial awareness and participation. It got me thinking again about the enterprise of clinical trials, and just how much goes in to clinical trial enrollment.
Tuesday, July 25, 2017
I’d known her for almost three years. She had advanced ovarian cancer—clear cell—and was diagnosed with disease already in her chest, stage IV. She had a terrific response to neoadjuvant chemotherapy, which had resolved her extra-abdominal disease sites after three cycles. She had an aggressive interval surgery that achieved complete resection of residual cancer (an R0 resection). She had completed adjuvant chemotherapy and I declared her to be in remission at that time—but it was short-lived; within four months, her disease had returned. Platinum resistance, we call it. We started a new regimen then—not for cure, I told her and her husband. The goal was control.
Thursday, June 15, 2017
In oncology, we strive for cure and short of that, we strive for stability. In some instances, particularly with recurrent disease, cure is rare, and the process of curative treatment can be quite extreme (for example, bone marrow transplantation for recurrent lymphoma, with the real risk of graft versus host disease substantial and, in its most extreme, debilitating). But in solid tumor oncology (for the most part), we have been driven toward less-toxic treatments, less-complicated regimens, while continuing to strive for better survival.
Thursday, May 25, 2017
I remember as a kid, my grandmother would spend time at our breakfast table reading the newspaper. Not cover to cover, mind you—she seemed to always focus her attention on the obituaries. Sometimes she would look up and tell anyone sitting around her about the death of someone near her age, or sometimes, someone very young. It was the first time I remember hearing how someone “lost the fight to cancer.” It is something I have heard many times since, and it continues to bother me. I’ve written before how the war analogy implies winners and losers, but even more than that, the analogy assumes only two outcomes: remission or death. No middle ground. And today more than ever, nothing is further from reality.